Abstract
Allogeneic myeloablative haematopoietic stem cell transplantation (HSCT) is challenged by severe adverse events, as cytotoxic effects of the conditioning may result in systemic inflammation, leaky epithelial barriers and organ toxicities, contributing to treatment-related morbidity and mortality. We hypothesised that insulin-like growth factor-1 (IGF-1), a mediator of growth and proliferation of various tissues, may attenuate chemotherapy-induced tissue damage after HSCT. We prospectively measured plasma levels of IGF-1 and its binding protein 3 (IGFBP-3) in 41 patients undergoing myeloablative HSCT. IGF-1 and IGFBP-3 levels were inversely correlated with C-reactive protein and interleukin-6 levels post HSCT. In multivariate analyses, low levels of IGF-1 and IGFBP-3 before conditioning were associated with increased risk of developing sinusoidal obstruction syndrome (SOS; OR=5.00 per 1 SDS decrease in IGF-1 (95% CI: 1.45–16.67), P=0.011 and OR=5.00 (1.37–20.00), P=0.015, respectively). Furthermore, low pre-transplant levels of IGF-1 and IGFBP-3 were associated with increased fluid retention during the first 21 days post transplant (OR=7.69 (95% CI: 1.59–33.33), P=0.012, and OR=2.94 (1.03–8.33), P=0.045). These data suggest that high levels of IGF-1 and IGFBP-3 may have a protective effect against fluid retention and SOS, possibly by attenuating systemic inflammation, and may prove useful as predictive biomarkers of SOS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Copelan EA . Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813–1826.
Ferrara JLM, Levine JE, Reddy P, Holler E . Graft-versus-host disease. Lancet 2009; 373: 1550–1561.
Hill GR, Ferrara JL . The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754–2759.
Carreras E, Diaz-Ricart M . The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant 2011; 46: 1495–1502.
Spruijt NE, Visser T, Leenen LP . A systematic review of randomized controlled trials exploring the effect of immunomodulative interventions on infection, organ failure, and mortality in trauma patients. Crit Care 2010; 14: R150.
Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2015; 50: 781–789.
DeLeve LD, Shulman HM, McDonald GB . Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22: 27–42.
Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant 2010; 16: 157–168.
Juul A . Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 2003; 13: 113–170.
Conover CA . Regulation and physiological role of insulin-like growth factor binding proteins. Endocr J 1996; 43: S43–S48.
Phillips LS, Pao CI, Villafuerte BC . Molecular regulation of insulin-like growth factor-I and its principal binding protein, IGFBP-3. Prog Nucleic Acid Res Mol Biol 1998; 60: 195–265.
Rajaram S, Baylink DJ, Mohan S . Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997; 18: 801–831.
Steenfos HH . Growth factors and wound healing. Scand J Plast Reconstr Surg Hand Surg 1994; 28: 95–105.
Xian CJ . Roles of growth factors in chemotherapy-induced intestinal mucosal damage repair. Curr Pharm Biotechnol 2003; 4: 260–269.
Howarth GS, Shoubridge CA . Enhancement of intestinal growth and repair by growth factors. Curr Opin Pharmacol 2001; 1: 568–574.
Liu SJ, Zhong Y, You XY, Liu WH, Li AQ, Liu SM . Insulin-like growth factor 1 opposes the effects of C-reactive protein on endothelial cell activation. Mol Cell Biochem 2014; 385: 199–205.
Thum T, Hoeber S, Froese S, Klink I, Stichtenoth DO, Galuppo P et al. Age-dependent impairment of endothelial progenitor cells is corrected by growth hormone mediated increase of insulin-like growth factor-1. Circ Res 2007; 100: 434–443.
Kielsen K, Jordan KK, Uhlving HH, Pontoppidan PL, Shamim Z, Ifversen M et al. T cell reconstitution in allogeneic haematopoietic stem cell transplantation: prognostic significance of plasma interleukin-7. Scand J Immunol 2015; 81: 72–80.
Department of Growth and Reproduction, Rigshospitalet Metodeliste: Copenhagen, Denmark, 2013. Available at: http://www.hormlabvejl.regionh.dk/Metodeliste.asp (accessed on 29 January 2017).
The Danish Accreditation Fund. Accreditation for Medical Examination. The Danish Accreditation Fund: Skovlunde, Denmark, 2013. Available at: http://published.danak.dk/register.asp?sag=06-1013&nohead=y&lang=e (accessed on 29 January 2017).
Rigby RA, Stasinopoulos DM . Generalized additive models for location, scale and shape. Appl Stat 2005; 54: 507–554.
Aksglaede L, Sorensen K, Petersen JH, Skakkebaek NE, Juul A . Recent decline in age at breast development: the copenhagen puberty study. Pediatrics 2009; 123: e932–e939.
Sørensen K, Aksglaede L, Petersen JH, Juul A . Recent changes in pubertal timing in healthy Danish boys: associations with body mass index. J Clin Endocrinol Metab 2010; 95: 263–270.
Damgaard-Olesen A, Johannsen TH, Holmboe SA, Søeborg T, Petersen JH, Andersson A et al. Reference ranges of 17-hydroxyprogesterone, DHEA, DHEAS, androstenedione, total and free testosterone determined by TurboFlow-LC-MS/MS and associations to health markers in 304 men. Clin Chim Acta 2016; 454: 82–88.
Pontoppidan PL, Jordan K, Carlsen AL, Uhlving HH, Kielsen K, Christensen M et al. Associations between gastrointestinal toxicity, micro RNA and cytokine production in patients undergoing myeloablative allogeneic stem cell transplantation. Int Immunopharmacol 2015; 25: 180–188.
Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A et al. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol 2013; 163: 444–457.
Shulman HM, Hinterberger W . Hepatic veno-occlusive disease—liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 197–214.
Dalle J-H, Giralt SA . Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant 2015; 22: 400–409.
Jeschke MG, Barrow RE, Herndon DN . Insulinlike growth factor I plus insulinlike growth factor binding protein 3 attenuates the proinflammatory acute phase response in severely burned children. Ann Surg 2000; 231: 246–252.
Jeschke MG, Barrow RE, Suzuki F, Rai J, Benjamin D, Herndon DN . IGF-I/IGFBP-3 equilibrates ratios of pro- to anti-inflammatory cytokines, which are predictors for organ function in severely burned pediatric patients. Mol Med 2002; 8: 238–246.
Succurro E, Andreozzi F, Sciacqua A, Sciaqua A, Hribal ML, Perticone F et al. Reciprocal association of plasma IGF-1 and interleukin-6 levels with cardiometabolic risk factors in nondiabetic subjects. Diabetes Care 2008; 31: 1886–1888.
Spies M, Wolf SE, Barrow RE, Jeschke MG, Hendon DN . Modulation of types I and II acute phase reactants with insulin-like growth factor-1/binding protein-3 complex in severely burned children. Crit Care Med 2002; 30: 83–88.
Al-Dasooqi N, Sonis ST, Bowen JM, Bateman E, Blijlevens N, Gibson RJ et al. Emerging evidence on the pathobiology of mucositis. Support Care Cancer 2013; 21: 3233–3241.
Ong ZY, Gibson RJ, Bowen JM, Stringer AM, Darby JM, Logan RM et al. Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol 2010; 5: 22.
Logan RM, Stringer AM, Bowen JM, Yeoh AS-J, Gibson RJ, Sonis ST et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 2007; 33: 448–460.
Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DMK . Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther 2008; 7: 1139–1145.
Schots R, Van Riet I, Othman TB, Trullemans F, De Waele M, Van Camp B et al. An early increase in serum levels of C-reactive protein is an independent risk factor for the occurrence of major complications and 100- day transplant-related mortality after allogeneic bone marrow transplantation. Bone Marrow Transplant 2002; 30: 441–446.
McNeer JL, Kletzel M, Rademaker A, Alford K, O’Day K, Schaefer C et al. Early elevation of C-reactive protein correlates with severe infection and nonrelapse mortality in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 350–357.
Pihusch M, Pihusch R, Fraunberger P, Pihusch V, Andreesen R, Kolb H-J et al. Evaluation of C-reactive protein, interleukin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients. Eur J Haematol 2006; 76: 93–101.
McDonald GB, Tabellini L, Storer BE, Lawler RL, Martin PJ, Hansen JA . Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. Blood 2015; 126: 113–120.
Wong WM, Wright NA . Epidermal growth factor, epidermal growth factor receptors, intestinal growth, and adaptation. JPEN J Parenter Enteral Nutr 1999; 23: S83–S88.
Dignass AU, Sturm A . Peptide growth factors in the intestine. Eur J Gastroenterol Hepatol 2001; 13: 763–770.
Howarth G . Enhancement of intestinal growth and repair by growth factors. Curr Opin Pharmacol 2001; 1: 568–574.
Booth D, Potten CS . Protection against mucosal injury by growth factors and cytokines. J Natl Cancer Inst Monogr 2001; 29: 16–20.
Huang KF, Chung DH, Herndon DN . Insulinlike growth factor 1 (IGF-1) reduces gut atrophy and bacterial translocation after severe burn injury. Arch Surg 1993; 128: 47–53.
Cool JC, Dyer JL, Xian CJ, Butler RN, Geier MS, Howarth GS . Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats. Growth Horm IGF Res 2005; 15: 72–82.
Eissner G, Multhoff G, Holler E . Influence of bacterial endotoxin on the allogenicity of human endothelial cells. Bone Marrow Transplant 1998; 21: 1286–1288.
Tichelli A, Gratwohl A . Vascular endothelium as ‘novel’ target of graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21: 139–148.
Palomo M, Diaz-Ricart M, Carbo C, Rovira M, Fernandez-Aviles F, Martine C et al. Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. Biol Blood Marrow Transplant 2010; 16: 985–993.
Palomo M, Mir E, Rovira M, Carreras E, Diaz-Ricart M . What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance. Blood 2016; 127: 1719–1727.
Tesfamariam B . Endothelial repair and regeneration following intimal injury. J Cardiovasc Transl Res 2016; 9: 91–101.
Conti E, Carrozza C, Capoluongo E, Volpe M, Crea F, Zuppi C et al. Insulin-like growth factor-1 as a vascular protective factor. Circulation 2004; 110: 2260–2265.
Higashi Y, Quevedo HC, Tiwari S, Sukhanov S, Shai SY, Anwar A et al. Interaction between insulin-like growth factor-1 and atherosclerosis and vascular aging. Front Horm Res 2014; 43: 107–124.
Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2016; 51: 906–912.
Howarth GS . Insulin-like growth factor-I and the gastrointestinal system: therapeutic indications and safety implications. J Nutr 2003; 133: 2109–2112.
Shimon I, Shpilberg O . The insulin-like growth factor system in regulation of normal and malignant hematopoiesis. Leuk Res 1995; 19: 233–240.
Acknowledgements
Financial support was obtained from The Danish Cancer Association and the Dagmar Marshall Foundation.
Author contributions
SW contributed to data collection, performed the statistical analyses and interpretation and drafted the manuscript. KK contributed to project design, data collection and data interpretation. HS, KJ, CHN and AJ participated in data collection. AJ, AEP and LPR contributed to project design. KGM designed the project, established the collaboration and contributed to data interpretation. All authors critically revised the manuscript and gave their final approval of the version to be published.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on Bone Marrow Transplantation website
Supplementary information
Rights and permissions
About this article
Cite this article
Weischendorff, S., Kielsen, K., Sengeløv, H. et al. Associations between levels of insulin-like growth factor 1 and sinusoidal obstruction syndrome after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 52, 863–869 (2017). https://doi.org/10.1038/bmt.2017.43
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2017.43
This article is cited by
-
Intra-iliac bone marrow injection as a novel alternative to intra-tibial inoculation in rat model
Stem Cell Research & Therapy (2021)
-
Insulin-like growth factor-I predicts sinusoidal obstruction syndrome following pediatric hematopoietic stem cell transplantation
Bone Marrow Transplantation (2021)
-
EASIX and mortality after allogeneic stem cell transplantation
Bone Marrow Transplantation (2020)